Aims: Prevention of type 2 diabetes (T2DM) is a priority in healthcare, but there is a lack of evidence investigating how to effectively translate prevention research into a UK primary care setting. We assessed whether a structured education programme targeting lifestyle and behaviour change was effective at preventing progression to T2DM in people with prediabetes..
INTRODUCTION

USA Diabetes Prevention Program (DPP).(6)
Despite the strong evidence for lifestyle interventions in the prevention of T2DM, there has been a translational gap between trial evidence and implementation into routine care. This is predominantly due to the resource-intensive nature of lifestyle interventions tested. For example, in the first year of the DPP programme, participants received 16 one hour one-toone counselling sessions followed by an average of eight additional contacts and two telephone consultations. Participants were also offered supervised exercise classes. (6) This intensity of care is incompatible with routine care pathways. Therefore, the emphasis needs to be shifted to examining the effectiveness of approaches designed for implementation within routine primary care. As healthcare services have differences in funding, organisation and infrastructure, programmes cannot be assumed to be generalizable across contexts. To date there has been a dearth of evidence concerning T2DM prevention in the UK, with small-scale projects showing mixed results. (7) (8) (9) (10) This study assesses whether the Let's Prevent T2DM programme is effective at preventing progression to T2DM in people with PDM identified through a systematic screening pathway within primary care. Let's Prevent is a pragmatic, relatively low resource, group-based structured-education programme targeting lifestyle behaviour change specifically designed for implementation within a community setting.
METHODS
The study had two phases. The first was a screening phase which identified people at risk of PDM/T2DM through the use of a screening tool that had been developed and validated for use within Primary Care. (11, 12) In the second phase, participants who had been screened and found to have PDM progressed to the cluster RCT. The cluster RCT design has been described in detail elsewhere. (13) The trial randomised practices to avoid the risk of contamination. Ethical approval was sought and the study involved practice level and individual level informed consent. Recruitment took place between May 2009 and June 2011, with follow up data collected up to July 2014.
Practices and participants
Practices in Leicestershire, UK, were recruited and randomised using a computer-generated list 1:1 to either the standard-care or intervention arm by an independent researcher, using stratification by list size (<6,000, ≥6,000), and ethnicity (percentage South Asian <21%, ≥21% -taken from ADDITION-Leicester study (14) ) with a block size of four. Practices and participants were informed of their allocation in the results letters after the screening/baseline measurements were complete. Eligible participants were identified from recruited practices via a two-stage screening process. The Leicester Diabetes Practice Risk Score was used in each practice to identify people at high-risk of PDM/T2DM for invitation to screening. (11) The top 10% of patients with the highest score fulfilling the inclusion criteria were invited.
The inclusion criteria for screening were aged 40 to 75 if White European, or 25-75 years if South Asian. Participants were excluded if they were unable to give informed consent, pregnant or lactating, had established diabetes or a terminal illness, or if they required an interpreter for a language other than one of the locally used South Asian languages accommodated within this study. All those agreeing to take part received an oral glucose tolerance test (OGTT). Only participants who were identified as having PDM (IFG and/or IGT WHO 1999 criteria (15)) during screening took part in the RCT. In one small practice (list size=1650) no participants were identified with PDM and was excluded.
The screening-visit data formed the baseline assessment for the RCT; participants were followed up at 6, 12, 24 and 36 months.
Interventions
All participants received an information booklet which included information on risk factors for T2DM, and how dietary and lifestyle changes and increased physical activity can prevent progression to T2DM.
Participants in the intervention practices were invited to attend the Let's Prevent programme, (13) which tailors the widely delivered DESMOND structured-education programme into a prevention context. (16, 17) Let's Prevent was delivered to groups of ten over six hours, either over a full-day or two halfdays, by two trained educators. The programme was underpinned by a theoretical basis with a philosophy centred on patient empowerment. The aim was to increase knowledge and promote realistic perceptions of PDM, and to promote health behaviour, with the aims of reducing body weight by 5%, limiting total and saturated fat intake to 30% and 10% of total energy intake respectively, increasing fibre intake and promoting physical activity. The physical activity section incorporated the successful PREPARE structured-education programme,(7) based on providing participants with a pedometer and enabling the formation of personalised step-per-day goals. The content and educational resources used within the programme were further tailored to the need of local South Asian populations, including delivery through interpreters where required. Educators were trained using an accredited pathway, and received ongoing support and quality development to ensure consistent delivery.
Participants were invited to three-hour refresher sessions at 12 and 24 months to reinforce key messages, review risk factors and update action plans. In addition, participants received a 15-minute telephone call every three months from healthcare professionals trained to offer on-going support in behaviour change. Those who did not attend the initial session were not invited to the refresher sessions, but continued to be followed up.
Outcome measures
All outcomes were measured at the participant level. The primary outcome was progression to T2DM during three years. T2DM diagnosis was defined according to WHO 1999 criteria/guidelines.(15) Participants without symptoms of diabetes in whom the initial OGTT showed T2DM were re-called for a second test to confirm the diagnosis. Participants found to have T2DM at baseline were excluded. Following the update of the WHO diagnostic criteria to include HbA1c (18) we obtained a protocol amendment in January 2013 allowing HbA1c ≥6.5% to become part of diagnostic criteria for T2DM within this study. Therefore T2DM was diagnosed using OGTT prior to January 2013, and with either an OGTT or HbA1c post January 2013. Participants and their GP were informed of the results. Diagnosis of T2DM within primary care was also captured by self-report followed by confirmation through GP records. Participants diagnosed with T2DM after baseline remained in the study to complete the questionnaires and other biomedical data, but did not undertake further OGTTs.
A full list of the secondary outcomes assessed at each time point is described elsewhere (13), these included: lipid levels, HbA1c, medical and medication history, blood pressure, weight, waist and body mass index (BMI). Participants also completed a questionnaire containing a number of validated questionnaires which assessed total self-reported physical activity, subsequently reported as metabolic equivalent minutes per week (METS.mins/wk), (19) (23) and sleep pattern; resource usage data and EQ-5D responses were also collected for the cost-effectiveness analysis.(24) Participants also wore a sealed pedometer (NL-800, New Lifestyles, Inc., Lees Summit, MO, USA) with a seven-day memory during waking hours to provide habitual ambulatory activity (average daily step count derived by summing total accumulated steps and dividing by days worn). For the purposes of this study, at least three valid days of data were required; a valid day constituted at least 10 hours of wear time (25) .
Other secondary outcomes included change in cardiovascular risk as calculated by the Framingham risk calculator, and presence of metabolic syndrome as defined by NCEP ATP III.
Sample Size
The sample size takes into account the clustering by GP practice. Assuming a three-year cumulative conversion rate to T2DM of 35% in the standard-care group (equivalent to 117 events per 1000 follow-up years), an intraclass correlation of 0.05, and 17 participants per practice (equal clusters assumed), we needed 280 per group to detect a 40% risk reduction in the intervention group. Allowing for a 25% drop-out rate, a total of 748 participants needed to be recruited.
Statistical analysis
A statistical-analysis plan was agreed before data were available. Practice and participant level characteristics were compared by group, using either means (SD) or medians (IQR) for continuous variables, and counts and percentages for nominal variables. Cluster randomisation gives balance with respect to cluster-level covariates but can lead to imbalance in participant level covariates; therefore differences were assessed using t-tests and chisquared tests.
Progression to T2DM was analysed on an intention-to-treat basis (ITT). The event rate per 1,000 person years was calculated by group. Participants were censored at the date of their last clinical appointment or at diagnosis of T2DM. Cox proportional hazards models with group as a covariate were fitted; practices were assumed to have the same frailty. Hazard ratios (HR) and 95% confidence intervals were presented. Subgroup analyses were performed by PDM status (IGT, IFG, IGT and IFG, HbA1c 6.0-6.4%).
For all secondary outcomes, participants who developed T2DM during the study had their last value from before their diagnosis carried forward for the remainder of the study. This method was used in a previous similar study.(7) All secondary outcomes were analysed using generalised estimating equation models with an exchangeable correlation structure, which adjusted for clustering. For binary outcomes we used a logit link with a binomial distribution for the outcome, and for continuous outcomes we used an identity link with a normal distribution. The analysis was repeated at each time point. The missing outcomes were not replaced and we derived an average of continuous outcomes over time. This procedure measures the cumulative effect of the intervention and has the maximum number of participants.
Subsidiary analyses were carried out for the main secondary outcomes at 12 and 36 months.
The analysis was repeated: (i) excluding those from the intervention group who did not attend the initial Let's Prevent education session (per-protocol); and (ii) imputing any missing values for the secondary outcomes using multiple imputation (ITT). The imputation was carried out using the command MI in Stata. MI replaces missing values with multiple sets of simulated values to complete the data, performs standard analysis on each completed dataset, and adjusts the obtained parameter estimates for missing-data uncertainty using Rubin's rules to combine estimates.(26) Adjustments were not made for multiple testing. All the results from the planned analyses have been reported and P values interpreted taking into account the overall pattern of the results. Statistical significance was set at 5%. All analyses were conducted using Stata version 13.
RESULTS
Overall, 43 practices were included; ranging in in size from 1,650-24,000. The median number of participants with PDM recruited per practice was 23 in the standard-care arm and 17 in the intervention arm; the number recruited per practice ranged from 2-49. In total 880 participants were recruited (433 standard care, 447 intervention, Figure 1 ). At 36 months 76% of the intervention group attended compared to 79% in the standard-care arm (p=0.43).
Compared to those who attended at 36 months, non-attenders were more likely to be smokers, and from more socially-deprived locations (Table A.1). Of those participants from practices randomised to the intervention, 101 (22.6%) did not attend the initial education session and were excluded in per-protocol analyses. Compared to those who attended, non-attenders were younger, more likely to be male, from more socially deprived locations, more likely to be smokers, and less physically active (see Table A .2).
At baseline a higher levels of deprivation and smokers were seen in the intervention group (Table 1) . Weight (p=0.0002), BMI (p=0.003) and waist circumference (p=0.0001) were significantly higher in the standard-care group compared to the intervention group. person years in the standard-care group (Figure A.1) . The hazard ratio (HR) showed a nonsignificant 26% reduced risk of developing T2DM in the intervention arm compared to standard-care (p=0.18). The effect was greater (35% reduction) in the per-protocol analysis albeit still non-significant (p=0.07) ( Table 2 ). The risk of developing T2DM in the intervention group compared to standard-care was similar across all sub-groups of PDM. The ICC for the development of T2DM was 0.02 (95% CI 0, 0.05). 
Secondary outcomes
In both groups improvements were seen for many secondary outcomes, see Table 3 for a summary and A.3-A.6 for the full results. A statistically significant reduction of 0.06% in HbA1c was seen in the intervention group compared to the standard-care group when analysing the mean across all time points. Significant reductions in LDL-cholesterol were seen at 12 months and overall. For all other outcomes, apart from systolic blood pressure, a greater improvement was seen in the intervention group than the standard-care group at 36
months, but none of these reached statistical significance. No differences were seen for CVD/CHD risk outcomes or the presence of metabolic syndrome.
Improvements during the study were seen in illness perceptions, quality of life and anxiety in the intervention group compared to the standard-care group. Fat intake was not significantly reduced in the intervention group compared to the standard-care group, but statistically significant increases in unsaturated fat were reported. Although no differences between the intervention and standard-care group were seen in the self-reported levels of activity, a significant reduction in sitting time of 30 minutes per day or more was seen in the intervention group at 12 and 24 months and overall, compared to the standard-care group.
There was also an increase in objectively measured average daily step-count in the intervention group of 450-500 steps per day at all time points, with a significant effect seen at 12, 36 months and overall. 
Subsidiary analyses
In the per-protocol analysis, significant reductions at 36 months were seen for fasting (-0.12 mmol/l), 2-hour (-0.35 mmol/l) and HbA1c (-0.11%) in the intervention compared to standard-care (Table 4 ). The increase in step-count in the intervention group compared to standard-care was increased in the per-protocol analysis. For the intention-to-treat analysis, the interpretation of the results for the secondary outcomes assessed did not change.
Table 4 Key secondary outcomes -Subsidiary analysis
Coefficients show intervention effect adjusted for baseline value and cluster. Complete case -data analysed according to randomised group; those with missing data excluded on a case-by-case basis. Per protocol -those randomised to the intervention who did not attend the initial education are excluded. Intention to treat -data analysed according to randomised group, all randomised participants included. Missing data imputed using multiple imputation. 
DISCUSSION
To our knowledge, this is the first study investigating the effectiveness of a T2DM prevention programme within primary care in the UK. We have shown that a pragmatic, low-resource, three-year T2DM prevention programme, based on a six-hour, group-based, structurededucation session followed by two annual group-based sessions and nine telephone contacts, can lead to improvements in markers of metabolic health, psychosocial wellbeing, and health behaviour. The primary outcome of the study was reduction in progression to T2DM; although non-significant, a modest 25% reduction in progression was observed in those receiving the education intervention, which increased to 35% when excluding those who did not attend the first education session.
Our study has several strengths and limitations. Strengths include using a rigorous design to evaluate the effectiveness of the programme specially developed for delivery within a multiethnic primary care setting. The primary limitation was that this study was underpowered due to the discrepancy between predicted and observed incidence rates of T2DM. The observed incidence rates of 63.16 events per 1,000 person years in the standard-care arm were substantially lower than anticipated, and consistent with those observed in non-intervention settings. (27) This acted to substantially reduce the study power, resulting in wider confidence intervals and a greater likelihood of a type 2 error. In addition, the variation in cluster size was greater than planned (the number of participants recruited per practice ranged from 2-49, further diluting power. However, the estimates of the ICC (0.05) and the inflation for drop out (25%) used were adequate (0.02 and 24% respectively). Although the reduction in the risk of T2DM was not statistically significant, the effect size was similar to the Indian Diabetes Prevention programme, which reported a 28.9% reduction in the risk of T2DM following a lifestyle intervention.(28) Limitations inherent in cluster randomised studies were also observed here, particularly achieving a balance in participant characteristics across groups: important differences at baseline were observed, with the intervention group having higher levels of social deprivation and smoking rates, but with lower levels of BMI and waist circumference. These differences could have acted to confound the result. Finally, the generalizability of the findings should be assessed cautiously. Of those invited for screening, 19% attended. (12) Although this uptake rate is consistent with other studies in similar populations (29, 30) and reflects the difficulty of recruiting a multi-ethnic urban population into prevention studies, it may limit the generalizability of the findings. Higher rates of uptake would be expected in a non-research setting: for example, the NHS Health Checks programme has 40% uptake.(31) Due to ethical constraints, no data extracted from primary care regarding those invited for screening. Therefore we cannot compare the characteristics of the invited cohort to those who attended to establish if there was any potential for bias. A study of similar design conducted in the same area screening for T2DM found that the 22% who attended screening were older and more likely to be female. (30) Only 23% of the intervention group attended the initial education, ad-hoc analyses suggest the intervention effect can be increased as attendance increases. Future studies should focus on strategies to increase uptake to screening and attendance/compliance with the programme.
We observed several improvements in secondary outcomes. Importantly, there was evidence that the programme reduced threatening perceptions of PDM, anxiety and improved overall quality of life. This is consistent with other structured-education programmes. (16 The results seen here reflect those seen in other similar trials, (28, 34) and have been interpreted in terms of clinical as well as statistical importance.
Our study extends evidence for efficacy of lifestyle interventions in the prevention of T2DM into in a primary care setting. There is now evidence internationally that T2DM prevention programmes can be tailored for, and translated into, primary health care and community settings, with modest short-term effects on markers of health status, such as body weight. (35) However, longer-term studies designed to quantify effectiveness on reducing progression to T2DM are lacking. This has resulted in a lack of evidence-based solutions that might enable primary care organisations to conform to NICE guidance for the prevention of T2DM. Here we show that this approach can be adapted to the prevention of T2DM within a diverse multi-ethnic PDM population whilst using less than 25% of the contact time seen in other efficacy trials. Future research is needed to investigate how the approach used in Let's Prevent can be tailored to individual preferences concerning the frequency and format of contact. In particular, utilising web-based platforms is likely to receive a growing focus in the future.
A separate paper assesses the cost effectiveness of the intervention. In brief, this showed the education programme was associated with higher costs (£168) and higher quality of life (0.046 QALYs) compared to the standard care group over three years. Therefore, the Let's Prevent programme is likely to be cost effective at a willingness to pay threshold of £20,000
per QALY gained.(39)
CONCLUSION
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